|
Salmedix is fixated on blood. The drug-development company focuses on treatments for hematologic malignancies, or blood cancers. Lead product candidate Treanda is in clinical testing as a therapy for slow-progressing non-Hodgkin's lymphoma (NHL). Salmedix obtained the rights to develop and market the drug in North America from a firm in Germany, where the drug (known as Ribomustin) has been aiding patients with NHL for more than 10 years. Salmedix has two other clinical-stage products, SDX-101 and SDX-102, that may treat related types of cancer. Several other candidates that may treat prostate cancer and leukemia also are in preclinical studies. Cephalon bought the company in mid-2005.
|
| | | Contact Information | |
Address: |
9381 Judicial Dr., Ste. 160
San Diego, CA 92121
| | Phone: | 858-622-5050 | | Fax: | 858-622-5060 |
|
| Financial
Highlights | | Fiscal Year End: | December |
|
|
Key People
| | • |
Chairman, President, and CEO:
David S. Kabakoff
| | • |
CFO, Chief Administrative Officer, and Secretary:
Anita I. Busquets
| | • |
SVP, Corporate Development:
Wendy S. Johnson
|
|
|
